X

Vous n'êtes pas connecté

  - NEWS.MEDICAL.NET - A la Une - 10/Jan 16:44

Breakthrough microscopy technique reveals how antibodies target cancer cells

In blood cancers such as chronic lymphocytic leukaemia, B cells of the immune system multiply uncontrollably.

Articles similaires

Sorry! Image not available at this time

Credit-card-sized chip reveals how immune cells hunt and kill cancer in real time

wn.com - 01/Jul 23:27

A credit-card-sized chip may soon outsmart cancer. A team led by NYU Tandon School of Engineering’s Weiqiang Chen has developed a miniature device...

Sorry! Image not available at this time

Credit-card-sized chip reveals how immune cells hunt and kill cancer in real time

wn.com - 01/Jul 23:27

A credit-card-sized chip may soon outsmart cancer. A team led by NYU Tandon School of Engineering’s Weiqiang Chen has developed a miniature device...

Researchers uncover surprising role of ‘natural killer’ cells in resistance to cancer immunotherapy

oncologynews.com.au - 30/Jun 18:35

Melanoma, one of the deadliest forms of skin cancer, affects an estimated 330,000 people worldwide each year and causes nearly 60,000 deaths...

Researchers uncover surprising role of ‘natural killer’ cells in resistance to cancer immunotherapy

oncologynews.com.au - 30/Jun 18:35

Melanoma, one of the deadliest forms of skin cancer, affects an estimated 330,000 people worldwide each year and causes nearly 60,000 deaths...

Malaria protein plays dual role in immune evasion and activation

news.medical.net - 24/Jun 13:49

Researchers from The University of Osaka find that a protein expressed on malaria-infected red blood cells both hides it from the immune system and...

Fixed-duration acalabrutinib-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting

oncologynews.com.au - 24/Jun 16:53

A fixed-duration regimen of acalabrutinib in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU)...

Fixed-duration acalabrutinib-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting

oncologynews.com.au - 24/Jun 16:53

A fixed-duration regimen of acalabrutinib in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU)...

Sorry! Image not available at this time

Breakthrough Links Gut Microbiome to Treatment Resistance and Stress-Related Inflammation

wn.com - 24/Jun 18:31

New research from Kawasaki Medical School reveals how gut bacteria influence treatment resistance and stress-related inflammation in chronic digestive...

Sorry! Image not available at this time

Breakthrough Links Gut Microbiome to Treatment Resistance and Stress-Related Inflammation

wn.com - 24/Jun 18:31

New research from Kawasaki Medical School reveals how gut bacteria influence treatment resistance and stress-related inflammation in chronic digestive...

Australian-led breakthrough in stem cell transplant for blood cancers set to change 40 years of standard practice

oncologynews.com.au - 23/Jun 18:46

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly...

Les derniers communiqués

  • Aucun élément